Company Overview and News

Pantoro has consistent strong gold production in March quarter

Pantoro Ltd (ASX:PNR) produced a solid 13,385 ounces of gold in the March quarter from its 100% owned Nicolsons Gold Mine within the Halls Creek Project in Western Australia.
Upvote Downvote

Pantoro extends gold mineralisation at Wagtail underground mine

Pantoro Ltd (ASX:PNR) has extended the depth and strike of gold mineralisation at the Wagtail underground mine in Western Australia’s Kimberley region.
Upvote Downvote

Pantoro is a low-cost gold producer with plenty of growth opportunities

Pantoro Ltd (ASX:PNR) is producing gold from its 100% owned Nicolsons Gold Mine within the Halls Creek Project in Western Australia.
Upvote Downvote

Pantoro debt-free after making early final repayment to CBA

Pantoro Ltd (ASX:PNR) is a zero-debt company after making its final repayment under the gold pre-payment facility with the Commonwealth Bank of Australia (ASX:CBA).
Upvote Downvote

Pantoro reveals high-grade gold depth extensions in drilling at Nicolsons

Pantoro Ltd (ASX:PNR) has identified deep high-grade gold extensions at the Nicolsons underground mine which forms part of the Halls Creek project in Western Australia.
Upvote Downvote

Pantoro high-grade gold hits highlight regional potential of Nicolsons project

Pantoro Ltd (ASX:PNR) continues to highlight the golden potential of its Nicolsons project area in Western Australia by way of high-grade results from the Western Reef regional target.
Upvote Downvote

Pantoro makes strategic move to expand portfolio in gold producing region

Pantoro Ltd (ASX:PNR) continues its consolidation of gold prospects in the Halls Creek region of Western Australia by entering a binding agreement to acquire the Mary River Gold Project.
Upvote Downvote

Pantoro AISC below A$1000 ($US780) in another record breaking quarter of production

Pantoro Ltd (ASX:PNR) continues to lower costs breaking another production record at its high-grade gold operation within the Halls Creek Project in Western Australia.
Upvote Downvote

Pantoro updating gold resources ahead of underground development

Pantoro Ltd (ASX:PNR) aims to update gold resources and reserves before beginning underground development of the Wagtail mine at its Nicolsons operations in Western Australia.
Upvote Downvote

Pantoro’s golden run sets new record

Pantoro Ltd (ASX:PNR) has recorded the tenth consecutive quarter of increased production from its Nicolsons Mine in Western Australia.
Upvote Downvote

Pantoro bringing in new ore sorter to facilitate expansion of gold production

Pantoro Ltd (ASX:PNR) has placed an order for and committed to the installation of a STEINART multi-sensor ore sorter at the Nicolsons gold mine in Western Australia.
Upvote Downvote

Pantoro bringing in new ore sorter to facilitate expansion of gold production

Pantoro Ltd (ASX:PNR) has placed an order for and committed to the installation of a STEINART multi-sensor ore sorter at the Nicolsons gold mine in Western Australia.
Upvote Downvote

Pantoro drills out an underground future at open-pit gold mine

Pantoro (ASX:PNR) has drilled out extensive high-grade gold mineralisation beneath its Wagtail and Rowdies open pits located near Halls Creek in Western Australia.
Upvote Downvote

Pantoro records ninth consecutive quarter of record gold production

Pantoro (ASX:PNR) increased gold production by 12% in the June quarter to 13,282 ounces from the Nicolsons Mine within its 100% owned Halls Creek Gold Project, Western Australia.
Upvote Downvote

Pantoro snaps up asset with potential for high-grade gold ore feed

Pantoro Ltd (ASX:PNR) has been producing gold from the Nicolsons project since September 2015, and recently delivered more gold production records.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...